Tscan Therapeutics, Inc. ( (TCRX) ) has released its Q4 earnings. Here is a breakdown of the information Tscan Therapeutics, Inc. presented to its investors.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment. The company recently reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs. TScan presented promising data from its ALLOHA Phase 1 heme trial, showing a lower relapse rate in treated patients compared to controls. The company also announced the clearance of an IND application for its seventh TCR in the PLEXI-T solid tumor program and completed a $30 million direct offering to extend its cash runway into 2027. Financially, TScan experienced a decline in revenue to $0.7 million for Q4 2024, down from $7.2 million in the same period the previous year, primarily due to changes in collaboration agreements. R&D expenses increased to $29.4 million for the quarter, reflecting ongoing clinical trial activities. Despite a net loss of $35.8 million for the quarter, TScan maintains a strong cash position of $290.1 million, supporting operations into early 2027. Looking ahead, TScan plans to continue advancing its pipeline with upcoming data presentations and trial initiations, positioning itself for potential growth in the field of cancer immunotherapy.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com